INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
GS
Corporate insider

Gray Susannah

DirectorCIK 0001833453

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 0
Max Insider Score9
Connections with evidence2

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
6,009 sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Theravance Biopharma, Inc.Director · Sep 24, 2026
  • Insider ofevidence
    ANAPTYSBIO, INCDirector · Apr 29, 2026
9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D
—
42.1K sh
Sep 23, 2026
Sep 24, 2026
traded Sep 23, 2026
+1d
SEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
32.7K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
22.0K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
23.6K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
24.3K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
13.4K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
ANABANAPTYSBIO, INC
Grant or award
A—
11.3K sh
Apr 27, 2026Apr 29, 2026
traded Apr 27, 2026
+2dSEC FORM 4

Evidence

Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago